Invasive tracheobronchial aspergillosis in a patient with thrombotic thrombocytopenic purpura (TTP ) and immunosuppressed due to the use of steroids and anti-CD 20

Jaime Madinaveitia Turcott; Alfredo Aisa Álvarez; Rafael Hurtado Monroy; Pablo Vargas Viveros; Juan Carlos Vázquez García; Juan Esponda Prado; Silvia Carrillo Ramírez; Cecilia Gallegos Garza

2014, Number 1

<< Back Next >>

Rev Fac Med UNAM 2014; 57 (1)

Invasive tracheobronchial aspergillosis in a patient with thrombotic thrombocytopenic purpura (TTP ) and immunosuppressed due to the use of steroids and anti-CD 20

Madinaveitia TJ, Aisa ÁA, Hurtado MR, Vargas VP, Vázquez GJC, Esponda PJ, Carrillo RS, Gallegos GC

Full text

How to cite this article

Language: Spanish
References: 26
Page: 31-38
PDF size: 249.95 Kb.

ABSTRACT

Invasive aspergillosis is a complication most commonly developed in immunosuppressed patients. Tracheobronquial aspergillosis is an extremely rare complication with minimal clinical expression. We present the case of a 53-year-old female patient diagnosed with thrombotic thrombocytopenic purpura (TTP) and immunosuppressed due to the use of steroids and anti-CD20, who presented hemoptisis twice; being the second one massive leading to death. Before the second event of hemoptisis, bronchoscopy was performed, which showed pseudomembranes and ulceration of the bronchial epithelium. In the post-mortem examination, the presence of Aspergillus was evidenced by both biopsy and culture. The presumption and early diagnosis of this condition are paramount for immunosuppressed patients due to its high mortality.

REFERENCES

Chang SM, Kuo HT, Lin FJ, Tzen CY, Sheu CY. Pseudomembranous tracheobronchitis caused by Aspergillus in immunocompromised patients. Scand J infect Dis. 2005; 37:937-42.
Young RC, Bennett JE, Vogel CL, Carbone PP, DeVita VT. Aspergillosis. The spectrum of the disease in 98 patients. Medicine (Baltimore). 1970;49:147-73.
Kemper CA, Hosteler JS, Follansbee SE, Ruane P, Covington DC, Leong SS, et al. Ulcerative and plaque-like tracheobronchitis due to infection with Aspergillus in patients with AIDS. Clin Infect Dis. 1993;7:344-52.
Kramer MR, Denning DW, Marshall SE, Ross DJ, Berry G, Lewiston NJ, Stevens DA, Theodore J. Ulcerative tracheobronchitis after lung transplantation. A new form of invasive aspergillosis. Am Rev Respir Dis. 1991;144:552-6.
Froissart A, Buffet M, Veyradier A, et al. Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center. Crit Care Med. 2012;40:104.
Patterson TF, Kirkpatrick WR, White M, et al. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. Aspergillus Study Group. Medicine (Baltimore). 2000;79:250-60.
Stevens DA, Kan VL, Judson MA, et al. Practice guidelines for diseases caused by Aspergillus. Clin Infect Dis. 2000;30:696-709.
Machida U, Kami M, Kanda Y, Takeuchi K, Akahane M, Yamaguchi I, et al. Aspergillus tracheobronchitis after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1999;24:1145-9.
Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-Fatality rate: Systematic review of the literature. Clin Infect Dis. 2001;32:358-66.
Denning DW. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 1996;23:608-15.
Mehrad B, Paciocco G, Martinez FJ, Ojo TC, Iannettoni MD, Lynch JP III. Spectrum of Aspergillus infection in lung transplant recipients: case series and review of the literature. Chest. 2001;119:169-75.
Sridhar M, Jeffers M, Brankin E, Soukop M, Banham S. Wheeze in a heart transplant patient with lymphoma. Postgrad Med J. 1995;71:375-7.
Tait RC, O’Driscoll BR, Denning DW. Unilateral wheeze caused by pseudomembranous Aspergillus tracheobronchitis in the immunocompromised patient. Thorax. 1993; 48:1285-7.
Gefter WB. The spectrum of pulmonary Aspergillosis. J Thorac Imaging. 1992;7:56-74.
Karnak D, Avery RK, Gildea TR, Sahoo D, Mehta AC. Endobronchial fungal disease: an under-recognized entity. Respiration. 2007;74:88-104.
Hines DW, Haber MH, Yaremko LS. Pseudomembranous tracheobronchitis caused by aspergillosis. Am Rev Respir Dis. 1991;143:1408-11.
Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis. 2002;34:563-71.
Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347:408-15.
Schwartz S, Ruhnke M, Ribaud P, et al. Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood. 2005;106:2641-5.
Barrett JP, Vardulaki KA, Conlon C, et al. A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clin Ther. 2003;25:1295-320.
Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis. 2007;44:2-12.
Marr KA, Boeckh M, Carter RA, et al. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis. 2004;39:797-802.
Van der Velden WJ, Blijlevens NM, Klont RR, Donnelly JP, Verweij PE. Primary hepatic invasive aspergillosis with progression after rituximab therapy for a post transplantation lymphoproliferative disorder. Ann Hematol. 2006;85:621-3.
Achan V, Williams FMK, Leach RM. Pulmonary aspergillosis and massive haemoptysis in systemic lupus erythematosus. Clin Intensive Care. 1996;7:102-7.
George JN, Al-Nouri ZD. Diagnostic and therapeutic challenges in the thrombotic thrombocytopenic purpura and hemolytic uremic syndromes. ASH Education Program. Hematology. 2012:604-9.
George JN. How I treat patients with thrombotic thrombocytopenic purpura-2010. Blood. 2010;116(20):4060-9.